CLL Case Review: IgHV-Unmutated Therapy Options
EP. 1: A Case Review of a 74-Year-Old Man With CLL
Watch
EP. 2: Triggers to Initiate Treatment in Patients With CLL
EP. 3: Considerations of Ibrutinib for IgHV-Unmutated CLL
EP. 4: Management of Toxicities in Frontline Ibrutinib Therapy
EP. 5: Sequencing After Frontline BTK Inhibition in CLL
EP. 6: Therapeutic Options for High-Risk CLL
